Bifalgorithm post · 10 Cancer Treatment Approvals From September 2026 and What They Mean for You · One Approval That Was Taken Away
Approval Withdrawal
Approval Withdrawal (10 Cancer Treatment Approvals From September 2026 and What They Mean for You · One Approval That Was Taken Away) — "On Sept. 1, the FDA wi…
Ideas in this flowchart
- The FDA withdrew accelerated approval for Krazati plus Erbitux in colorectal cancer.
- The withdrawal occurred on Sept. 1.
- The approved combination was Krazati (adagrasib) plus Erbitux (cetuximab).
- The treatment was intended for KRAS G12C-mutated colorectal cancer.
- A confirmatory trial did not show that the treatment helped people live longer than chemotherapy.
- CURE's coverage provides additional reporting on the decision.
